chartexchange

Photocure Provides Update on AssureMDx and Anticipated Medicare Coverage Timeline

Cision | Nov 9, 2026 2:00 AM EST

Press release – Oslo, Norway, November 9, 2026 – Photocure ASA (OSE: PHO), the Bladder Cancer Company, today provides an update on AssureMDx™ and progress since the acquisition of Vesica Health on June 4, 2026.

Since closing the acquisition, Photocure has continued to advance the commercial and reimbursement strategy for AssureMDx. Discussions with the relevant pricing authorities have been encouraging, with indications of a potential reimbursement level meaningfully above the assumptions included in Photocure’s initial acquisition underwriting.
AssureMDx received FDA Breakthrough Device

Read original article